Neurodegenerative Disease Market Size, Share, Trends, and Forecast 2028
Neurodegenerative Disease Market By Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington’s Disease, and Other Indication Types), By Drug Type (N-methyl-D-Aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, and Other Drug Types), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 - 2028-
Category: Healthcare Report Format : PDF
Pages: 241 Report Code: ZMR-2147
Published Date: Jul-2022 Status : Published
| Market Size in 2021 | Market Forecast in 2028 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 39892.5 million | USD 47911.88 million | 3.1% | 2021 |
Table Of Content
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market research methodology
- Chapter 2. Executive Summary
- 2.1 Global Neurodegenerative Disease Market, (2022 - 2028) (USD Million)
- 2.2 Global Neurodegenerative Disease Market : snapshot
- Chapter 3. Global Neurodegenerative Disease Market - Industry Analysis
- 3.1 Neurodegenerative Disease Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Increasing Prevalence of Alzheimer’s Disease Drives Market Growth
- 3.3 Market Restraints
- 3.3.1. Inadequate reimbursement policies may hamper the global market growth.
- 3.4 Market Opportunities
- 3.4.1. A robust drug pipeline for treating neurodegenerative diseases brings up several growth opportunities.
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market attractiveness analysis By Indication Type
- 3.7.2 Market attractiveness analysis By Drug Type
- Chapter 4. Global Neurodegenerative Disease Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Neurodegenerative Disease Market: company market share, 2021
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Neurodegenerative Disease Market - Indication Type Analysis
- 5.1 Global Neurodegenerative Disease Market overview: By Indication Type
- 5.1.1 Global Neurodegenerative Disease Market share, By Indication Type, 2021 and 2028
- 5.2 Parkinson's Disease
- 5.2.1 Global Neurodegenerative Disease Market by Parkinson's Disease, 2022 - 2028 (USD Million)
- 5.3 Alzheimer's Disease
- 5.3.1 Global Neurodegenerative Disease Market by Alzheimer's Disease, 2022 - 2028 (USD Million)
- 5.4 Multiple Sclerosis
- 5.4.1 Global Neurodegenerative Disease Market by Multiple Sclerosis, 2022 - 2028 (USD Million)
- 5.5 Huntington Disease
- 5.5.1 Global Neurodegenerative Disease Market by Huntington Disease, 2022 - 2028 (USD Million)
- 5.6 Other Indication Types
- 5.6.1 Global Neurodegenerative Disease Market by Other Indication Types, 2022 - 2028 (USD Million)
- 5.1 Global Neurodegenerative Disease Market overview: By Indication Type
- Chapter 6. Global Neurodegenerative Disease Market - Drug Type Analysis
- 6.1 Global Neurodegenerative Disease Market overview: By Drug Type
- 6.1.1 Global Neurodegenerative Disease Market share, By Drug Type, 2021 and 2028
- 6.2 N-methyl-D-aspartate Receptor antagonists
- 6.2.1 Global Neurodegenerative Disease Market by N-methyl-D-aspartate Receptor antagonists, 2022 - 2028 (USD Million)
- 6.3 Cholinesterase Inhibitors
- 6.3.1 Global Neurodegenerative Disease Market by Cholinesterase Inhibitors, 2022 - 2028 (USD Million)
- 6.4 Dopamine Agonists
- 6.4.1 Global Neurodegenerative Disease Market by Dopamine Agonists, 2022 - 2028 (USD Million)
- 6.5 Immunomodulatory Drugs
- 6.5.1 Global Neurodegenerative Disease Market by Immunomodulatory Drugs, 2022 - 2028 (USD Million)
- 6.6 Other Drug Types
- 6.6.1 Global Neurodegenerative Disease Market by Other Drug Types, 2022 - 2028 (USD Million)
- 6.1 Global Neurodegenerative Disease Market overview: By Drug Type
- Chapter 7. Neurodegenerative Disease Market - Regional Analysis
- 7.1 Global Neurodegenerative Disease Market Regional Overview
- 7.2 Global Neurodegenerative Disease Market Share, by Region, 2021 & 2028 (USD Million)
- 7.3. North America
- 7.3.1 North America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.3.1.1 North America Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
- 7.3.1 North America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.4 North America Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
- 7.4.1 North America Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
- 7.5 North America Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
- 7.5.1 North America Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
- 7.4. Europe
- 7.4.2 Europe Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.4.2.1 Europe Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
- 7.4.2 Europe Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.4 Europe Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
- 7.4.1 Europe Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
- 7.5 Europe Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
- 7.5.1 Europe Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
- 7.5. Asia Pacific
- 7.5.3 Asia Pacific Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.5.3.1 Asia Pacific Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
- 7.5.3 Asia Pacific Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.4 Asia Pacific Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
- 7.4.1 Asia Pacific Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
- 7.5 Asia Pacific Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
- 7.5.1 Asia Pacific Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
- 7.6. Latin America
- 7.6.4 Latin America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.6.4.1 Latin America Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
- 7.6.4 Latin America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.4 Latin America Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
- 7.4.1 Latin America Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
- 7.5 Latin America Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
- 7.5.1 Latin America Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
- 7.7. The Middle-East and Africa
- 7.7.5 The Middle-East and Africa Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.7.5.1 The Middle-East and Africa Neurodegenerative Disease Market, by Country, 2022 - 2028 (USD Million)
- 7.7.5 The Middle-East and Africa Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 7.4 The Middle-East and Africa Neurodegenerative Disease Market, by Indication Type, 2022 - 2028
- 7.4.1 The Middle-East and Africa Neurodegenerative Disease Market, by Indication Type, 2022 - 2028 (USD Million)
- 7.5 The Middle-East and Africa Neurodegenerative Disease Market, by Drug Type, 2022 - 2028
- 7.5.1 The Middle-East and Africa Neurodegenerative Disease Market, by Drug Type, 2022 - 2028 (USD Million)
- Chapter 8. Company Profiles
- 8.1 Biogen Inc
- 8.1.1 Overview
- 8.1.2 Financials
- 8.1.3 Product Portfolio
- 8.1.4 Business Strategy
- 8.1.5 Recent Developments
- 8.2 Abbvie Inc
- 8.2.1 Overview
- 8.2.2 Financials
- 8.2.3 Product Portfolio
- 8.2.4 Business Strategy
- 8.2.5 Recent Developments
- 8.3 UCB SA
- 8.3.1 Overview
- 8.3.2 Financials
- 8.3.3 Product Portfolio
- 8.3.4 Business Strategy
- 8.3.5 Recent Developments
- 8.4 Amneal Pharmaceuticals Inc
- 8.4.1 Overview
- 8.4.2 Financials
- 8.4.3 Product Portfolio
- 8.4.4 Business Strategy
- 8.4.5 Recent Developments
- 8.5 Teva Pharmaceuticals Ltd
- 8.5.1 Overview
- 8.5.2 Financials
- 8.5.3 Product Portfolio
- 8.5.4 Business Strategy
- 8.5.5 Recent Developments
- 8.6 Boehringer Ingelheim International GmbHF
- 8.6.1 Overview
- 8.6.2 Financials
- 8.6.3 Product Portfolio
- 8.6.4 Business Strategy
- 8.6.5 Recent Developments
- 8.7 Pfizer Inc
- 8.7.1 Overview
- 8.7.2 Financials
- 8.7.3 Product Portfolio
- 8.7.4 Business Strategy
- 8.7.5 Recent Developments
- 8.8 Hoffmann-La Roche
- 8.8.1 Overview
- 8.8.2 Financials
- 8.8.3 Product Portfolio
- 8.8.4 Business Strategy
- 8.8.5 Recent Developments
- 8.9 Novartis AG
- 8.9.1 Overview
- 8.9.2 Financials
- 8.9.3 Product Portfolio
- 8.9.4 Business Strategy
- 8.9.5 Recent Developments
- 8.10 Merck & Co. Inc.
- 8.10.1 Overview
- 8.10.2 Financials
- 8.10.3 Product Portfolio
- 8.10.4 Business Strategy
- 8.10.5 Recent Developments
- 8.1 Biogen Inc
Table Of Figures
- 1. Market research Type
- 2. Market research methodology
- 3. Global Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 4. Porter’s Five Forces Analysis
- 5. Global Neurodegenerative Disease Market attractiveness, By Indication Type
- 6. Global Neurodegenerative Disease Market attractiveness, By Drug Type
- 7. Global Neurodegenerative Disease Market share by Indication Type, 2022 and 2028 (USD Million)
- 8. Global Neurodegenerative Disease Market by Parkinson's Disease, 2022 - 2028 (USD Million)
- 9. Global Neurodegenerative Disease Market by Alzheimer's Disease, 2022 - 2028 (USD Million)
- 10. Global Neurodegenerative Disease Market by Multiple Sclerosis, 2022 - 2028 (USD Million)
- 11. Global Neurodegenerative Disease Market by Huntington Disease, 2022 - 2028 (USD Million)
- 12. Global Neurodegenerative Disease Market by Other Indication Types, 2022 - 2028 (USD Million)
- 13. Global Neurodegenerative Disease Market share by Drug Type, 2022 and 2028 (USD Million)
- 14. Global Neurodegenerative Disease Market by N-methyl-D-aspartate Receptor antagonists, 2022 - 2028 (USD Million)
- 15. Global Neurodegenerative Disease Market by Cholinesterase Inhibitors, 2022 - 2028 (USD Million)
- 16. Global Neurodegenerative Disease Market by Dopamine Agonists, 2022 - 2028 (USD Million)
- 17. Global Neurodegenerative Disease Market by Immunomodulatory Drugs, 2022 - 2028 (USD Million)
- 18. Global Neurodegenerative Disease Market by Other Drug Types, 2022 - 2028 (USD Million)
- 19. Global Neurodegenerative Disease Market share, by Region, 2022 and 2028
- 20. North America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 21. Europe Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 22. Asia Pacific Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 23. Latin America Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
- 24. The Middle-East and Africa Neurodegenerative Disease Market, 2022 - 2028 (USD Million)
Table Of Tables
- 1. Global Neurodegenerative Disease Market: Snapshot
- 2. Drivers of the Neurodegenerative Disease Market: impact analysis
- 3. North America Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 4. North America Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 5. U.S. Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 6. U.S. Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 7. Canada Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 8. Canada Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 9. Europe Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 10. Europe Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 11. Germany Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 12. Germany Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 13. France Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 14. France Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 15. U.K. Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 16. U.K. Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 17. Italy Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 18. Italy Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 19. Spain Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 20. Spain Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 21. Rest of Europe Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 22. Rest of Europe Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 23. Asia Pacific Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 24. Asia Pacific Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 25. China Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 26. China Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 27. Japan Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 28. Japan Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 29. India Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 30. India Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 31. South Korea Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 32. South Korea Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 33. South-East Asia Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 34. South-East Asia Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 35. Rest of Asia Pacific Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 36. Rest of Asia Pacific Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 37. Latin America Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 38. Latin America Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 39. Brazil Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 40. Brazil Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 41. Mexico Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 42. Mexico Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 43. Rest of Latin America Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 44. Rest of Latin America Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 45. The Middle-East and Africa Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 46. The Middle-East and Africa Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 47. GCC Countries Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 48. GCC Countries Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 49. South Africa Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 50. South Africa Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
- 51. Rest of Middle-East Africa Neurodegenerative Disease Market revenue, By Indication Type, 2022 - 2028 (USD Million)
- 52. Rest of Middle-East Africa Neurodegenerative Disease Market revenue, By Drug Type, 2022 - 2028 (USD Million)
Methodology
FrequentlyAsked Questions
The increasing prevalence of neurodegenerative disorders, an aging population, and rising demands for Parkinson's and Alzheimer's treatment options are all likely to drive significant growth in the neurodegenerative disease treatment market.
According to the report, the global neurodegenerative disease market was worth about 39892.5 (USD million) in 2021 and is predicted to grow to around 47911.88 (USD million) by 2028 with a compound annual growth rate (CAGR) of about 3.1 percent.
North America dominates the neurodegenerative disease market and accounts for more than 3.1 percent of the global revenue. The expansion of the neurodegenerative diseases industry in North America is driven by rising medication demand, high prices, growing R&D investment, and favorable health reimbursement policies. Furthermore, the region's neurodegenerative disease industry has also increased due to advancements in revolutionary technology for neurodegenerative disease medical care and a comprehensive product pipeline for wasting disorders.
Some of the main competitors dominating the global neurodegenerative disease market include - Biogen Inc, Abbvie Inc, UCB SA, Amneal Pharmaceuticals Inc, Teva Pharmaceuticals Ltd, Boehringer Ingelheim International GmbHF, Pfizer Inc, Hoffmann-La Roche, Novartis AG, and Merck & Co. Inc.
RelatedNews
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed